Game-changing pan-TEAD inhibitor for solid tumours
Drug Target Review
JUNE 12, 2023
With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. Can you provide a summary of the key findings and implications of the preclinical studies on ISM6331 for the treatment of advanced solid tumours?
92 
Let's personalize your content